AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 172 min read$NRXP

NRX Pharmaceuticals, Inc. (NRXP): Results of Operations and Financial Condition

NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. nrxp20260817_8k.htm false 0001719406 0001719406 2026-08-17 2026-08-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

Original reporting
SEC EDGAR 8-K
Published Aug 17, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$NRXP
Neutral
low confidence
Mentioned
$NRXP
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NRXPNeutralLow
01

Why it matters

The filing itself is a procedural disclosure that the earnings press release exists; the trading-relevant impact depends on the specific Q2 financials and any guidance or operational updates contained in Exhibit 99.1, which are not included in the provided text.

02

Market read

Traders should treat this as an earnings-release trigger for NRXP, but the provided scrape does not contain the numbers needed to form a directional view.

03

What to watch

Traders should verify whether Exhibit 99.1 includes material items such as cash burn, runway, R&D milestones, or any updated clinical/regulatory timelines, which are not present here.

Relevance 7/10Novelty 2/10Timing: filed Aug 17, 2026, pre-market/early session for the Q2 results release

Background

The SEC 8-K (Item 2.02) states NRX Pharmaceuticals announced its second-quarter 2026 results for the quarter ended June 30, 2026 and furnished the press release as Exhibit 99.1.

Company-level read

Ticker impact

$NRXPNeutralLow confidence
Context

NRX Pharmaceuticals filed an 8-K stating it announced Q2 2026 results for the quarter ended June 30, 2026 via Exhibit 99.1.

Expected impact

Near-term volatility possible on the actual Q2 numbers once traders read Exhibit 99.1, but direction cannot be inferred from the provided text.

Evidence & confidence

The body only confirms the existence of a Q2 results press release furnished as Exhibit 99.1, without reporting any figures, outlook, or operational updates.

Market effects

Sector

Limited from the provided text because no drug pipeline, trial, or guidance specifics are disclosed.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the scraped content omits the actual Q2 results, the market reaction may be driven by details in Exhibit 99.1 rather than the mere filing.

Key entities

  • issuer
    NRX Pharmaceuticals, Inc.

    Company filing Form 8-K for Q2 2026 results (Item 2.02) and furnishing Exhibit 99.1 press release.

  • document
    Exhibit 99.1

    Press release dated August 17, 2026 containing the actual Q2 results details.

Read at source← All news

Related articles

AUG 10
$NRXPMed

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

NRx Pharmaceuticals (NASDAQ:NRXP) said it submitted an FDA attestation for its preservative-free ketamine ANDA, describing it as a final verification step, though it has not received a new GDUFA action date. The company plans launch inventory of 4-5 million vials and expects shipping within days of approval. It targets hospitals and other settings and also plans branded NRX-100/NRX-101.

yahoo.com4 min
AUG 7
$NRXPMedAI 8/10

NRx Pharmaceuticals, Inc.: FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

NRx Pharmaceuticals (Nasdaq: NRXP) said the FDA completed the first-cycle review of its ANDA for preservative-free IV ketamine, finding no major deficiencies in the drug product, ingredients, labeling, or CMC. A remaining packaging-related issue concerns luer lock vial certification. FDA will review the requested manufacturer attestation in the shortest possible cycle. No new clinical data are required.

finanznachrichten.de4 min
JUN 25
$NRXPMed

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals said its subsidiary HOPE Therapeutics has treated its first patients using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System. HOPE installed systems in West Palm Beach and Sarasota, Florida, and began AI-guided, markerless TMS for major depressive disorder and other CNS conditions. NRx said this supports its planned NRX-101 plus robotic-enabled TMS SPARC-TMS trial.

manilatimes.net4 min
JUN 10
$NRXPMedAI 8/10

NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share

The article is largely promotional and does not provide verifiable details about NRx Pharmaceuticals. It states that NRx Pharmaceuticals (NRXP) closed an underwritten public offering of common stock at $3.50 per share, but it includes no offering size, proceeds, or investor impact data. The remainder focuses on AI-themed commentary and newsletter subscription offers.

insidermonkey.com4 min
JUN 4
$NRXPMedAI 9/10

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

NRx Pharmaceuticals (Nasdaq: NRXP) said it closed its underwritten public offering of common stock at $3.50 per share, including the underwriters’ option. Gross proceeds were about $22.3 million before underwriting discounts and expenses. BTIG was lead bookrunning manager and Lucid joint bookrunning manager; proceeds will be used for working capital and general corporate purposes.

manilatimes.net4 min